NCT03627312 is a Phase 2, PHASE3 clinical trial of Omega-3 in Antisocial Behavior, sponsored by Singapore Prison Service.

Who is sponsoring NCT03627312?

NCT03627312 is sponsored by Singapore Prison Service.

What drugs are being tested in NCT03627312?

Interventions in NCT03627312: Omega-3, Placebo, Treatment as Usual.

What condition does NCT03627312 study?

NCT03627312 studies Antisocial Behavior.

Is NCT03627312 still recruiting?

NCT03627312 is currently completed. Last updated 13 August 2018.

Last reviewed 2018-08-13 · How we verify

NCT03627312

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders

Completed Phase 2, PHASE3 Last updated 13 August 2018

What this trial tests

Phase 2, PHASE3 trial testing Omega-3 in Antisocial Behavior in 181 participants. Completed in 31 July 2013.

Timeline

1 March 2011

Primary endpoint
31 July 2013

31 July 2013

Quick facts

Lead sponsor	Singapore Prison Service
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	181
Start date	1 March 2011
Primary completion	31 July 2013
Estimated completion	31 July 2013

Drugs / interventions tested

Omega-3
Placebo
Treatment as Usual

Conditions studied

Antisocial Behavior — all drugs for Antisocial Behavior →

Sponsor

Singapore Prison Service

Who can join

Adults 16 to 21, male only, with Antisocial Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to examine the effects of providing omega-3 supplements on young offenders' antisocial behaviour. Participants will be randomized into three groups: (1) Omega-3, (2) Placebo and (3) Treatment as Usual. Self report and correctional officer ratings of behaviour will be assessed at 0 months (baseline), 3 months (end of supplementation), 6 months and 12 months. The investigators hypothesize that omega-3 supplementation will reduce antisocial behaviour among the young offenders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Omega-3

Trials testing the same drug.

NCT07136519 — Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting
NCT06538324 — Response to an Intervention With Omega-3 (RIO - Study) · NA · completed
NCT05990712 — The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammator · Phase 4 · unknown
NCT05711810 — Medicine-induced Cardiac Hemodialysis on COVID-19 · Phase 4 · completed
NCT07365553 — Omega-3, Autism Spectrum Disorder (ASD) · NA · recruiting

Other recruiting trials for Antisocial Behavior

Currently open trials in the same condition.

NCT06981351 — Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03627312 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Singapore Prison Service
Last refreshed: 13 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03627312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing